版本:
中国

BRIEF-Zynerba Pharma achieves target enrollment in exploratory phase 2 trial of ZYN002 in fragile X syndrome

June 8 Zynerba Pharmaceuticals Inc

* Zynerba Pharmaceuticals achieves target enrollment in exploratory phase 2 trial of ZYN002 in fragile X syndrome Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐